DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Azactam (Aztreonam) - Side Effects and Adverse Reactions



Local reactions such as phlebitis/thrombophlebitis following intravenous administration, and discomfort/swelling at the injection site following intramuscular administration occurred at rates of approximately 1.9% and 2.4%, respectively.

Systemic reactions (considered to be related to therapy or of uncertain etiology) occurring at an incidence of 1% to 1.3% include diarrhea, nausea and/or vomiting, and rash. Reactions occurring at an incidence of less than 1% are listed within each body system in order of decreasing severity:

Hypersensitivity—anaphylaxis, angioedema, bronchospasm

Hematologic—pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis

Gastrointestinal—abdominal cramps; rare cases of C. difficile–associated diarrhea, including pseudomembranous colitis, or gastrointestinal bleeding have been reported. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment. (See WARNINGS.)

Dermatologic—toxic epidermal necrolysis (see WARNINGS), purpura, erythema multiforme, exfoliative dermatitis, urticaria, petechiae, pruritus, diaphoresis

Cardiovascular—hypotension, transient ECG changes (ventricular bigeminy and PVC), flushing

Respiratory—wheezing, dyspnea, chest pain

Hepatobiliary—hepatitis, jaundice

Nervous System—seizure, confusion, vertigo, paresthesia, insomnia, dizziness

Musculoskeletal—muscular aches

Special Senses—tinnitus, diplopia, mouth ulcer, altered taste, numb tongue, sneezing, nasal congestion, halitosis

Other—vaginal candidiasis, vaginitis, breast tenderness

Body as a Whole—weakness, headache, fever, malaise

Pediatric Adverse Reactions

Of the 612 pediatric patients who were treated with AZACTAM in clinical trials, less than 1% required discontinuation of therapy due to adverse events. The following systemic adverse events, regardless of drug relationship, occurred in at least 1% of treated patients in domestic clinical trials: rash (4.3%), diarrhea (1.4%), and fever (1.0%). These adverse events were comparable to those observed in adult clinical trials.

In 343 pediatric patients receiving intravenous therapy, the following local reactions were noted: pain (12%), erythema (2.9%), induration (0.9%), and phlebitis (2.1%). In the US patient population, pain occurred in 1.5% of patients, while each of the remaining 3 local reactions had an incidence of 0.5%.

The following laboratory adverse events, regardless of drug relationship, occurred in at least 1% of treated patients: increased eosinophils (6.3%), increased platelets (3.6%), neutropenia (3.2%), increased AST (3.8%), increased ALT (6.5%), and increased serum creatinine (5.8%).

In US pediatric clinical trials, neutropenia (absolute neutrophil count less than 1000/mm3) occurred in 11.3% of patients (8/71) younger than 2 years receiving 30 mg/kg every 6 hours. AST and ALT elevations to greater than 3 times the upper limit of normal were noted in 15% to 20% of patients aged 2 years or above receiving 50 mg/kg every 6 hours. The increased frequency of these reported laboratory adverse events may be due to either increased severity of illness treated or higher doses of AZACTAM administered.

Adverse Laboratory Changes

Adverse laboratory changes without regard to drug relationship that were reported during clinical trials were:

Hepatic—elevations of AST (SGOT), ALT (SGPT), and alkaline phosphatase; signs or symptoms of hepatobiliary dysfunction occurred in less than 1% of recipients (see above).

Hematologic—increases in prothrombin and partial thromboplastin times, positive Coombs’ test.

Renal—increases in serum creatinine.


Below is a sample of reports where side effects / adverse reactions may be related to Azactam. The information is not vetted and should not be considered as verified clinical evidence.

Possible Azactam side effects / adverse reactions in 76 year old female

Reported by a health professional (non-physician/pharmacist) from France on 2011-12-07

Patient: 76 year old female

Reactions: Pruritus, Rash Maculo-Papular

Adverse event resulted in: hospitalization

Suspect drug(s):
    Start date: 2011-08-10
    End date: 2011-10-07

    Start date: 2011-08-13
    End date: 2011-10-10

Fucidine CAP
    Start date: 2011-08-12
    End date: 2011-10-07

Other drugs received by patient: Aldactone; Tenormin; Allopurinol; Nexium; Atarax; Prazepam; Fluoxetine; Irbesartan

Possible Azactam side effects / adverse reactions in 41 year old male

Reported by a consumer/non-health professional from United States on 2012-02-24

Patient: 41 year old male

Reactions: Expired Drug Administered

Suspect drug(s):

Possible Azactam side effects / adverse reactions in 85 year old female

Reported by a consumer/non-health professional from United States on 2012-04-03

Patient: 85 year old female

Reactions: Mental Impairment, Asthenia, Lethargy

Adverse event resulted in: death, hospitalization

Suspect drug(s):
    Indication: Urinary Tract Infection
    Start date: 2010-04-04

    Dosage: 400 mg 12h iv
    Indication: Urinary Tract Infection
    Start date: 2010-04-04
    End date: 2010-04-13

Other drugs received by patient: Cyanocobalamine IM; Tear Solution; Aspirin; Ketotifen Fumarate; Heparin; Potassium Chloride; Dorzolamine Ophthalmic Solution; Carvedilol; Insulin Aspart

See index of all Azactam side effect reports >>

Drug label data at the top of this Page last updated: 2013-06-17

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017